Affordable treatment reduces the burden on the healthcare services and increases the chances of NICE approval. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Ms Man-Chie Chow from the Royal Surrey County Hospital, Guildford, UK discusses how NICE may assess new treatments alongside lenalidomide for multiple myeloma and provides an overview of the methods that pharmaceutical companies can use to make new treatments more affordable whilst adhering to ABPI rules.
Analyzing the affordability of additional multiple myeloma drugs
